Reference
Summary Safety Review - Cholinesterase inhibitors (donepezil-, rivastigmine- and galantamine-containing products) - Health Canada Internet Document : 27 Jul 2022. Available from: URL: https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&linkID=SSR00285
Rights and permissions
About this article
Cite this article
Cholinesterase inhibitors: risk of QT-interval prolongation, torsade de pointes. Reactions Weekly 1917, 3 (2022). https://doi.org/10.1007/s40278-022-19874-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-19874-2